HIV and ID Observations

September 6th, 2010

Treating Cellulitis: Getting the Answer Wrong and Right

What’s the right antibiotic choice for cellulitis in the era of community-acquired MRSA? As astutely pointed out by Anne in her comment, the “correct” answer to the recertification question was #4, trimethoprim-sulfamethoxazole, for the following reason: I am not a doctor, I am a test developer. Having exactly zero knowledge about the content here (could […]

---

September 1st, 2010

Testing your Testing Skills

Have I whined yet about how I’m part of the first Internal Medicine class that was not “grandfathered” through to eternal board certfication?  If not, now I have. So for you fellow test-takers, here’s another one for you, adapted somewhat from this delightful experience I’m required to go through every 10 years.  Oddly, just like the […]

---

August 30th, 2010

Required Reading: In Love and “Serodiscordant”

Being of a certain age, my wife and I still subscribe to the print version of the Sunday New York Times.  Since we also get the local rag, quite a bit of paper is deposited on our doorstep each week. Worth it?  You bet, especially since occasionally there’s a gem in there like this week’s […]

---

August 26th, 2010

Lyme Cases Up — Anecdotes, True Epidemiology, and More Anecdotes

All of us New England-based ID doctors (and internists and family practitioners and pediatricians and NPs/PAs in primary care) who have been in practice a while will tell you that Lyme cases have been increasing for years. And it’s not just the number of cases, it’s also where and when they are occurring.  A few years […]

---

August 10th, 2010

Curbside Consults: The Yin and the Yang

One of the simultaneously most enjoyable and exasperating aspects of being an Infectious Disease specialist is the large volume of “curbside” consultations we get from colleagues. For example, here’s this week’s talley — and it’s only Tuesday — done from memory and without systematically keeping track of emails, pages, phone calls, etc.: Duration of antibiotics […]

---

July 19th, 2010

Vienna IAS: First (Really) Positive Microbicide Study

Big news from Vienna and Science, imminently: The CAPRISA 004 trial assessed effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the prevention of HIV acquisition in women. A double-blind, randomized controlled trial was conducted comparing tenofovir gel (n = 445) with placebo gel (n = 444) in sexually active, HIV-uninfected 18- to 40-year-old […]

---

July 6th, 2010

Torrid Tuesday

Some ID/HIV-related items for a sweltering summer day: Are the AIDS Drug Assistance Programs (ADAPs) in trouble?  Certainly in some states they are, and this interview gives additional perspective.  But I wonder — how much of this is HIV-specific, and how much is just the ongoing lousy economy.  In other words, are other government-funded programs comparably stressed?  […]

---

July 1st, 2010

RFA-AI-10-009, HIV Cure, and “Berlin Patient” Update

Interesting “RFA” (Request for Application, #RFA-AI-10-009) from Bethesda: The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health (NIMH), National Institutes of Health (NIH), encourage grant applications from institutions/organizations to address the problem of HIV-1 persistence in HIV-1-infected persons treated with suppressive antiretroviral drug regimens… The goal of this […]

---

June 16th, 2010

Another HIV Drug Development Program Bows Out

Last month, Avexa announced that they will not be going forward with their development of the investigational NRTI apricitabine. Now Myriad says its program to develop bevirimat is closing as well. The problems with these drugs — twice daily dosing with apricitabine, formulation and mixed responses with bevirimat — are not the real story here, since […]

---

June 11th, 2010

Plays at the (Culture) Plate

Some quick ID/HIV/other thoughts while we marvel in all that is Strasburgian: Did you know that HIV medication adherence improves over time? So much for “pill fatigue.” By the way, this anecdotally fits with my experience as well. And right now, the biggest reason for patients’ stopping their HIV meds is financial, usually due to loss of or […]

---